tislelizumab
beigene
[]
 tislelizumab + ctx vs ctx as 1l for #gastroesophageal cancer
@ asco-gi 2023 rationale-305 phs-iii, 549 pts pdl1+ (pd-l1&gt;5%) mos 17.6 vs 12.6 mo mpfs 7.2 vs 5.9 mo orr 50.4 vs 43% additional support for io in pd-l1+ gastric cancer, itt awaited 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine